Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - meloxicam -

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - omeprazole -

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - lisinopril dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - amoxycillin trihydrate; amoxycillin -

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - meropenem trihydrate -

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - clorazepate dipotassium (unii: 63fn7g03xy) (clorazepic acid - unii:d51wo0g0l4) - clorazepate dipotassium 3.75 mg - clorazepate dipotassium tablets, usp are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. clorazepate dipotassium tablets, usp are indicated as adjunctive therapy in the management of partial seizures. the effectiveness of clorazepate dipotassium tablets, usp in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. long-term studies in epileptic patients, however, have shown continued therapeutic activity. the physician should reassess periodically the usefulness of the drug for the individual patient. clorazepate dipotassium tablets, usp are indicated for the symptomatic relief of acute alcohol withdrawal. clorazepate dipotassium tablets are contraindicated in patients with a known hypersensitivity to the drug and in those with acute narrow angle glaucoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - losartan potassium 100mg - film coated tablet - 100 mg - active: losartan potassium 100mg excipient: colloidal silicon dioxide isopropyl alcohol lactose magnesium stearate   methylene chloride microcrystalline cellulose   opadry white 20h58983 pregelatinised maize starch   purified talc - ranbaxy-losartan is indicated for the treatment of hypertension. ranbaxy-losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy ranbaxy-losartan is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to ranbaxy-losartan is not recommended. ranbaxy-losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - losartan potassium 12.5mg - film coated tablet - 12.5 mg - active: losartan potassium 12.5mg excipient: colloidal silicon dioxide isopropyl alcohol lactose magnesium stearate   methylene chloride microcrystalline cellulose   opadry white 20h58983 pregelatinised maize starch   purified talc - ranbaxy-losartan is indicated for the treatment of hypertension. ranbaxy-losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy ranbaxy-losartan is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to ranbaxy-losartan is not recommended. ranbaxy-losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - losartan potassium 25mg - film coated tablet - 25 mg - active: losartan potassium 25mg excipient: colloidal silicon dioxide isopropyl alcohol lactose magnesium stearate   methylene chloride microcrystalline cellulose   opadry white 20h58983 pregelatinised maize starch   purified talc - ranbaxy-losartan is indicated for the treatment of hypertension. ranbaxy-losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy ranbaxy-losartan is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to ranbaxy-losartan is not recommended. ranbaxy-losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - losartan potassium 50mg - film coated tablet - 50 mg - active: losartan potassium 50mg excipient: colloidal silicon dioxide isopropyl alcohol lactose magnesium stearate   methylene chloride microcrystalline cellulose   opadry white 20h58983 pregelatinised maize starch   purified talc - ranbaxy-losartan is indicated for the treatment of hypertension. ranbaxy-losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy ranbaxy-losartan is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to ranbaxy-losartan is not recommended. ranbaxy-losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.